- Datum11.12.2025
- Uhrzeit17:00 - 17:30 Uhr
- Veranstalter
stock3
Novavax Inc. Aktie
Verkaufen
Kaufen
Novavax Inc. Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Novavax Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
3,89 %
Intraday
9,62 %
1 Woche
-18,43 %
1 Monat
-13,56 %
Seit Jahresbeginn
-20,57 %
1 Jahr
-57,98 %
3 Jahre
-93,23 %
5 Jahre
-95,65 %
10 Jahre
Passender Service zu Novavax Inc.
Webinar zu Novavax Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)5,010-11,550
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Novavax Inc.
Keine Dividenden verfügbar
Termine von Novavax Inc.
- Mär4Novavax Inc.Q4 2025 Earnings Release
- Mai13Novavax Inc.Q1 2026 Earnings Release
- Aug12Novavax Inc.Q2 2026 Earnings Release
Beschreibung
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
